(Q35040779)

6 August 2017

1 reference

title

Novel therapies for the treatment of inflammatory airway disease (English)

1 reference

6 August 2017

2

Maria G Belvisi

1 reference

6 August 2017

1

David J Hele

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

Expert Opinion on Investigational Drugs

6 August 2017

published in

1 reference

6 August 2017

volume

12

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

5-18

1 reference

6 August 2017

cites work

New treatments for COPD.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Recent advances: Respiratory medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Asthma therapy in the new millennium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

The global burden of disease, 1990–2020

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

New treatments for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Cellular and structural bases of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

History and future perspectives of treating asthma as a systemic and small airways disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Modulation of nicotine self-administration in rats by combination therapy with agents blocking alpha 3 beta 4 nicotinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Pharmacologic actions of the second generation leukotriene B4 receptor antagonist LY29311: in vivo pulmonary studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Reversal of human neutrophil survival by leukotriene B(4) receptor blockade and 5-lipoxygenase and 5-lipoxygenase activating protein inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Sputum chemotactic activity in chronic obstructive pulmonary disease: effect of alpha(1)-antitrypsin deficiency and the role of leukotriene B(4) and interleukin 8

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Chemokine receptors in airway disease: which receptors to target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

The role of CC chemokine receptor 2 in alveolar monocyte and neutrophil immigration in intact mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Tumor necrosis factor-alpha converting enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Pharmacological profile of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-alpha converting enzyme and matrix metalloproteinases, in models of airway inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Protection from pulmonary fibrosis in leukotriene-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic acid (NVP-ABE171), a 1,7-naphthyridine derivative, with anti-inflammatory activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Role of p38 MAP kinase in LPS-induced airway inflammation in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Acute cigarette smoke-induced connective tissue breakdown requires both neutrophils and macrophage metalloelastase in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Synthetic serine elastase inhibitor reduces cigarette smoke-induced emphysema in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Neutrophil elastase inhibitors as treatment for COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

A novel oral neutrophil elastase inhibitor (ONO-6818) inhibits human neutrophil elastase-induced emphysema in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Thiol-dependent enzymes and their inhibitors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

KCO912: a potent and selective opener of ATP-dependent potassium (K(ATP)) channels which suppresses airways hyperreactivity at doses devoid of cardiovascular effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

CTLA4-IgG reverses asthma manifestations in a mild but not in a more "severe" ongoing murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Novel drugs for treating asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Anti-T-cell strategies in the treatment of allergic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Anti-IgE as novel therapy for the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Monoclonal anti-IgE antibody: a novel therapy for allergic airways disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Leukotrienes in respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

The role of leukotrienes in upper and lower airway inflammation and the implications for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Loss of response to treatment with leukotriene receptor antagonists but not inhaled corticosteroids in patients over 50 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Regulation of the inflammatory response in asthma by mast cell products

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Inhibition of allergen-induced pulmonary responses by the selective tryptase inhibitor 1,5-bis-[4-[(3-carbamimidoyl-benzenesulfonylamino)-methyl]-phenoxy]-pen tane (AMG-126737).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

New anti-asthma therapies: suppression of the effect of interleukin (IL)-4 and IL-5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

New approaches in the treatment of asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Interleukins-4, -5, and -13: emerging therapeutic targets in allergic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Anti-tumor necrosis factor therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Soluble cytokine receptors in biological therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Cytokine modulators as novel therapies for asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

IL-10: a potential therapy for allergic inflammation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Chemokine receptors: multifaceted therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

CCR3 blockade as a new therapy for asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Chemokines and their receptors guiding T lymphocyte recruitment in lung inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Adenosine receptor ligands: potential as therapeutic agents in asthma and COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Discovery and development of respirable antisense therapeutics for asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Effects of CGS 21680, a selective adenosine A2A receptor agonist, on allergic airways inflammation in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Involvement of A(3) receptors in the potentiation by adenosine of the inhibitory effect of theophylline on human eosinophil degranulation: possible novel mechanism of the anti-inflammatory action of theophylline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Peroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Peroxisome proliferator-activated receptor gamma agonists: potential use for treating chronic inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Lipoxins are potential endogenous antiinflammatory mediators in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

21 January 2018

DNA therapy for asthma

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Overview of the innervation of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Cough: potential pharmacological developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Pharmacology of airway irritability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Effect of dopamine receptor agonists on sensory nerve activity: possible therapeutic targets for the treatment of asthma and COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

The burden of asthma and chronic obstructive pulmonary disease: data from The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

Clinical efficacy of bupropion in the management of smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.5

21 January 2018

Identifiers

DOI

10.1517/13543784.12.1.5

1 reference

6 August 2017

1 reference